Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | Day Return | YTD Return |
|---|---|---|---|
| All Industries | 100% | 0.16% | 1.98% |
| Drug Manufacturers - General | 34.21% | 1.63% | 8.04% |
| Healthcare Plans | 13.29% | -0.42% | -5.52% |
| Medical Devices | 12.90% | -0.70% | 3.52% |
| Diagnostics & Research | 11.44% | -0.90% | 2.08% |
| Biotechnology | 11.07% | -0.48% | -8.01% |
| Medical Instruments & Supplies | 6.66% | -0.38% | 2.61% |
| Medical Care Facilities | 2.91% | 0.56% | 9.60% |
| Drug Manufacturers - Specialty & Generic | 2.76% | 0.29% | -6.08% |
| Medical Distribution | 2.43% | -0.28% | 10.69% |
| Health Information Services | 2.09% | -3.61% | 4.89% |
| Pharmaceutical Retailers | 0.24% | -1.23% | -31.61% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
-
Largest Companies in This Sector
|
Name
|
Last Price
|
1Y Target Est.
|
Market Weight
|
Market Cap
|
Day Change %
|
YTD Return
|
Avg. Analyst Rating
|
|---|---|---|---|---|---|---|---|
| 782.30 | 826.94 | 11.72% |
|
|
|
Buy
|
|
| 483.92 | 566.61 | 7.02% |
|
|
|
Buy
|
|
| 145.23 | 162.32 | 5.52% |
|
|
|
Buy
|
|
| 129.90 | 140.82 | 5.19% |
|
|
|
Buy
|
|
| 162.26 | 184.07 | 4.53% |
|
|
|
Buy
|
|
| 571.97 | 616.78 | 3.44% |
|
|
|
Buy
|
|
| 106.27 | 118.35 | 2.91% |
|
|
|
Buy
|
|
| 245.72 | 252.85 | 2.87% |
|
|
|
Buy
|
|
| 274.43 | 286.05 | 2.32% |
|
|
|
Buy
|
|
| 25.64 | 29.05 | 2.29% |
|
|
|
Buy
|
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
|
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 140.60 | 41.319B | 0.09% |
|
|
| 256.81 | 21.195B | 0.10% |
|
|
| 127.33 | 7.632B | 0.45% |
|
|
| 85.20 | 7.551B | 0.35% |
|
|
| 55.19 | 5.76B | 0.40% |
|
Mutual Fund Opportunities
|
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 207.26 | 47.432B | 0.29% |
|
|
| 87.39 | 47.432B | 0.29% |
|
|
| 128.38 | 21.195B | 0.10% |
|
|
| 90.22 | 15.399B | 0.80% |
|
|
| 92.74 | 15.399B | 0.80% |
|
Healthcare Research
Discover the Latest Analyst and Technical Research for This Sector
-
Analyst Report: Elevance Health Inc
Elevance is a health benefits company. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members and an array of fee-based administrative managed care services. The company operates in the pharmacy services business. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, payment integrity services, and health and wellness programs, as well as services related to data management, information technology, and business operations. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance is headquartered in Indianapolis, Indiana. ELV is a component of the S&P 500.
RatingPrice Target -
Market Update: KBH, KLAC, ROP, SLB, ELV
With earnings season in full swing, the volume of insider transactions has fallen to seasonal lows, with only 615 transactions meeting the criteria for inclusion in Vickers Weekly Insider Report. While that is down from the recent weekly high of 2,284 transactions, there is still noteworthy data to consider.
-
Analyst Report: Novartis AG
Novartis is a pharmaceutical company based in Switzerland. Its portfolio is focused primarily on the areas of Immunology, Neuroscience, Oncology, Cardiovascular, Renal, and Metabolic therapies. The company employs more than 78,000 people and its medicines reach more than 280 million people worldwide.
RatingPrice Target -
Daily – Vickers Top Insider Picks for 04/30/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
